Akademik Veri Yönetim Sistemi
GROWTH HORMONE & IGF RESEARCH, cilt.82, 2025 (SCI-Expanded, Scopus)
Background Cabergoline, a dopamine agonist widely used in prolactinoma treatment, also suppresses growth hormone (GH) and insulin-like growth factor-1 (IGF-1), though its long-term effects on IGF-1 levels in prolactinoma remain unclear. Objective To evaluate changes in IGF-1 levels and influencing factors in prolactinoma patients treated with cabergoline. Methods This retrospective cohort study included 127 prolactinoma patients treated with cabergoline between 2013 and 2023. Patients with conditions affecting IGF-1 (e.g., hypopituitarism, organ dysfunction, hormone replacement therapy) were excluded. IGF-1 and IGF-1xULN levels were compared at baseline and last follow-up. Associations with treatment duration, cumulative cabergoline dose, and tumor features were assessed using regression and ROC analyses. Results The median follow-up was 36 [IQR: 18-60] months. Final IGF-1 and IGF-1xULN levels were significantly lower than baseline (p = 0.002 and p = 0.045). IGF-1xULN increased in 44.9 % and decreased in 55.1 % of patients, but all values remained within normal limits. Decreased IGF-1xULN was associated with longer treatment duration and higher cumulative doses (p < 0.05). ROC analysis identified >= 60 mg cumulative dose and >= 18 months treatment duration as predictors of IGF-1 reduction (AUROC approximate to 0.70). Conclusion Cabergoline therapy in prolactinoma may result in an early rise and subsequent decline in IGF-1 levels. The clinical significance of within-range IGF-1 reductions remains uncertain and requires prospective studies with predefined metabolic endpoints.